# The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome

> **NCT06328166** · NA · COMPLETED · sponsor: **Tri-Service General Hospital** · enrollment: 24 (actual)

## Conditions studied

- Carpal Tunnel Syndrome

## Interventions

- **PROCEDURE:** Sono-guided injection with ES135
- **PROCEDURE:** Sono-guided injection with placebo

## Key facts

- **NCT ID:** NCT06328166
- **Lead sponsor:** Tri-Service General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-22
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-05-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06328166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06328166, "The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06328166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*